Abstracts tagged "Myositis"

Abstract Number: 1076 • ACR Convergence 2020
Anti-Jo1 Antibody Quantification Serve as a Prognostic Factor in Anti-synthetase Syndrom
Lois Bolko¹, Kevin Didier², Jean-Hugues Salmon¹, Makoto Miyara³, Segolene Toquet², Amelie Servettaz², Yves Allenbach³, Olivier Benveniste⁴ and Baptiste Hervier⁵, ¹Maison Blanche Hospital, Reims, Champagne-Ardenne, France, ²Robert Debre Hospital, Reims, Champagne-Ardenne, France, ³Sorbonne Université, Paris, Ile-de-France, France, ⁴Sorbonne Université, paris, France, ⁵Saint-Louis Hospital, Paris, Ile-de-France, France
Background/Purpose: Anti-Synthetase Syndrome (ASyS) is a rare systemic autoimmune disease defined by a combination of pulmonary, muscle, joint, and skin manifestations and the presence of…
Abstract Number: 1098 • ACR Convergence 2020
Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis
Iago Pinal-Fernandez¹, Katherine Pak², Albert Gil-Vila³, Andres Baucells⁴, Benjamin Plotz⁵, Maria Casal-Dominguez⁶, Assia Derfoul⁷, Maria Angeles Martinez⁴, Albert Selva-O'Callaghan³, Sara Sabbagh⁸, Frederick W. Miller¹, Lisa G. Rider⁹, Lisa Christopher-Stine¹⁰ and Andrew Mammen⁶, ¹National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Vall d’Hebron Hospital, Barcelona, Spain, ⁴Sant Pau Hospital, Barcelona, Spain, ⁵Division of Rheumatology, New York University Langone Health, New York, NY, ⁶NIH, Bethesda, MD, ⁷NIAMS, NIH, Bethesda, ⁸Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Washington, DC, ⁹Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.Methods: In this longitudinal cohort study, anti-cortactin autoantibody tiers were…
Abstract Number: 1056 • ACR Convergence 2020
Descriptive Data Analysis of Patients with Anti Jo1 Syndrome (AJS) and Lung Involvement
Mohamed Alalwani¹, Bassam Alhaddad², Basem Zraik³, Christopher O'Rourke³, Ruchi Yadav³, Ali Askari¹, Charles Malemud¹ and Soumya Chatterjee⁴, ¹Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, OH, ²MetroHealth Medical Center, Westlake, OH, ³Cleveland Clinic, Cleveland, OH, ⁴Cleveland Clinic, Richmond Heights, OH
Background/Purpose: To evaluate the patterns, severity and, prognostic parameters of interstitial lung disease (ILD) in Anti Jo1 Syndrome (AJS).Methods: We identified 51 anti-Jo-1 patients with…
Abstract Number: 1077 • ACR Convergence 2020
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle Fiber Death, and Ameliorates Muscle Weakness in Experimental Polymyositis
Mari Kamiya¹, Seon Uk Kim², Jeong Yeon Kim³, Shinsuke Yasuda⁴, Eun Young Lee⁵ and Fumitaka Mizoguchi¹, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Jongno-gu, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, ⁴Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM). However, the treatment with GC causes GC-induced myopathy, which further deteriorates the muscle…
Abstract Number: 1099 • ACR Convergence 2020
High Burden of Infections in Indian Patients with Idiopathic Inflammatory Myopathy: Validation of Observations from the MyoCite Dataset
Rudrarpan Chatterjee¹, Pankti Mehta², Vikas Agarwal¹ and Latika Gupta², ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, lucknow, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Infections are a major cause of morbidity and mortality in idiopathic inflammatory myopathy (IIM), more so in India.[1-3] The objective of this study was…
Abstract Number: 082 • 2020 Pediatric Rheumatology Symposium
Anti-Mitochondrial Autoantibodies Are Associated with Dysphagia in Juvenile and Adult Myositis, and with Persistent Weakness and Cardiomyopathy in Adult Myositis
Sara Sabbagh¹, Iago Pinal-Fernandez ², Maria Casal-Dominguez ³, Frederick W. Miller ⁴, Lisa G. Rider ⁵, Andrew Mammen ³ and Lisa Christopher-Stine ⁶, ¹NIH/NIAMS, Bethesda, ²National Institutes of Health, Bethesda, ³NIH, Bethesda, ⁴Bethesda, ⁵NIEHS, NIH, Garrett Park, ⁶Johns Hopkins University, Baltimore
Background/Purpose: We analyzed the prevalence of anti-mitochondrial autoantibodies (AMA) in both juvenile-(JM) and adult-onset myositis cohorts and investigated phenotype differences between juvenile and adult myositis…
Abstract Number: 1286 • 2019 ACR/ARP Annual Meeting
Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis
Bret Sohn¹, Erin Wilfong ¹ and Leslie Crofford ¹, ¹Vanderbilt University, Nashville
Background/Purpose: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in idiopathic inflammatory myopathies (IIM) as well as systemic sclerosis (SSc). The…
Abstract Number: 1288 • 2019 ACR/ARP Annual Meeting
Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice
Fergus To¹, Clara Ventín Rodríguez ², Shuayb Elkhalifa ³, James Lilleker ⁴ and Hector Chinoy ⁴, ¹University of British Columbia, Vancouver, Canada, ²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³(3) Department of Immunology, Salford Royal NHS Foundation, Salford, United Kingdom, ⁴University of Manchester, Manchester, United Kingdom
Background/Purpose: To evaluate the real-world accuracy of a line blot immunoassay (LIA) for myositis-specific (MSA) and myositis-associated (MSA) autoantibody testing in patients at a tertiary…
Abstract Number: 1291 • 2019 ACR/ARP Annual Meeting
Semi-Quantitative and Quantitative Evaluation of Magnetic Resonance Imaging in Patients with Idiopathic Inflammatory Myopathies – a Subanalysis of the Prometheus Study
Katerina Kubinova¹ and Jiří Vencovský ², ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic
Background/Purpose: Prometheus study was a prospective, randomized, assessor-blind multicenter trial, comparing the efficacy and safety of the glucocorticoid (GC) monotherapy versus combination therapy with methotrexate…
Abstract Number: 1292 • 2019 ACR/ARP Annual Meeting
Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies
Sangmee Bae¹, Ilana Golub ², Ani Shahbazian ³, Jennifer Wang ³ and Christina Charles-Schoeman ⁴, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA Medical Center, Los Angeles, ⁴University of California, Los Angeles, CA
Background/Purpose: Vascular inflammation and damage are implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM), particularly dermatomyositis (DM). High and low density lipoprotein (HDL, LDL)…
Abstract Number: 1294 • 2019 ACR/ARP Annual Meeting
Alterations in Activin A-Myostatin-Follistatin System Associate with Disease Activity in Inflammatory Myopathies
Lucia Vernerová¹, Veronika Horvathová ², Tereza Kropáčková ³, Martina Vokurková ², Martin Klein ¹, Sabina Oreska ⁴, Katerina Kubinova ⁵, Herman Mann ⁴, Maja Spiritovic ⁶, Hana Storkanova ¹, Olga Kryštůfková ¹, Michal Tomcik ⁴, Jozef Ukropec ⁷, Barbara Ukropcová ⁷ and Jiří Vencovský ⁴, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Prague, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, ⁶Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague 2, Hlavni mesto Praha, Czech Republic, ⁷Institute of Experimental Endocrinology, Biomedical center, Slovak Academy of Sciences, Bratislava, Slovakia
Background/Purpose: The aim of this study was to investigate myokines involved in muscle atrophy such as myostatin, follistatin and activin A, in idiopathic inflammatory myopathies…
Abstract Number: 2245 • 2019 ACR/ARP Annual Meeting
Polymyositis (PM) and Dermatomyositis (DM) Symptom Flares and Associated Impact from the Patient Perspective
Lisa Christopher-Stine¹, William Kelly ², George Wan ³, Linda Kobert ⁴ and Michael Reed ⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins Myositis Center, Baltimore, MD, ³Mallinckrodt Pharmaceuticals, Bedminster, NJ, ⁴The Myositis Association, Alexandria, VA, ⁵Vedanta Research, Chapel Hill, NC
Background/Purpose: Flare activity or worsening symptoms are not well defined for myositis. This analysis characterizes PM and DM flares from the patient perspective and reports…
Abstract Number: 2840 • 2019 ACR/ARP Annual Meeting
Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy
Didem Saygin¹, Chester Oddis ¹, Nicole Neiman ¹, Diane Koontz ¹, Siamak Moghadam-Kia ¹ and Rohit Aggarwal ¹, ¹University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare, debilitating systemic diseases characterized by proximal muscle weakness, which limit activities of daily living and…
Abstract Number: 2844 • 2019 ACR/ARP Annual Meeting
Predictive Factors for Mortality in Anti-melanoma-associated Gene 5 Antibody-associated Interstitial Lung Disease
Takahisa Gono¹, Kenichi Masui ², Naoshi Nishina ³, Shinji Sato ⁴ and Masataka Kuwana ⁵, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Tokyo, Japan, ²Department of Anaesthesiology, Show University School of Medicine, Saitama, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan, ⁵Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is useful to predict mortality in patients with myositis–associated interstitial lung disease (ILD) because of high prevalence of…
Abstract Number: 2845 • 2019 ACR/ARP Annual Meeting
Pain Patterns in Idiopathic Inflammatory Myopathy (IIM): Associations with Disease Activity Measures (Muscle Enzymes, Manual Muscle Testing 8), Patient-Reported Quality of Life (HAQ) and Pain Scales (Widespread Pain Index (WPI), Symptom Severity Index (SSI) and Visual Analogue Scale)
Elena Schiopu¹, Sohail Farshad ², Nada Abdulaziz ³, Stacey Anderson ³ and Ann Impens ⁴, ¹Department of Rheumatology, University of Michigan, Ann Arbor, ²Department of Internal Medicine, Beaumont Health System, Royal Oak, MI, ³The University of Michigan, Ann Arbor, MI, ⁴Institute for Healthcare Innovation, Glendale, AZ
Background/Purpose: IIMs associate with significant lifelong disability due to progressive loss of muscle function and lack of curative interventions; little is known about the relative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.